The benefits of combining Akt2 inhibition with standard chemotherapy thus appear to be twofold; disruption of the Akt2 survival pathway in cancer cells that harbor constitutively active Akt may induce an apoptotic response, while inhibition of Akt may abrogate the undesired survival response seen when tumor cells are exposed to chemotherapy. This evidence concerns the gene AKT1 and cancer.